Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA
Source: SeekingAlpha
2026-03-26 17:26:51 ET
More on Nuvation Bio, Eisai
- Nuvation Bio Inc. (NUVB) Presents at The Citizens Life Sciences Conference 2026 Transcript
- Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
- Eli Lilly, Biogen/ Eisai win U.K. review for use of Alzheimer’s drugs in NHS
- Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships
Read the full article on Seeking Alpha
For further details see:
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA
Nuvation Bio Inc. Class A
NASDAQ: NUVB
NUVB Trading
-3.82% G/L:
$4.31 Last:
653,126 Volume:
$4.36 Open:
NUVB Latest News
April 01, 2026 08:00:00 am
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
March 26, 2026 04:05:00 pm
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 21, 2026 05:15:00 pm
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
NUVB Stock Data
$1,967,863,905
245,468,738
0.19%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
